TWA
ARQT icon

TCI Wealth Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

TCI Wealth Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-370
Closed -$4.07K – 348
2023
Q1 		$4.07K Buy
+370
New +$5.35K ﹤0.01% 1673
2021
Q3 		– Sell
-64
Closed -$2K – 2372
2021
Q2 		$2K Buy
+64
New +$1.8K ﹤0.01% 1947

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

TCI Wealth Advisors's ARQT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 370 shares — an estimated $4.07K sold.

TCI Wealth Advisors first reported a position in ARQT in Q2 2021 and held it in 2 quarters. The position peaked at $4.07K in Q1 2023. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 370 Arcutis Biotherapeutics shares in Q2 2023, an estimated $4.07K.
  • TCI Wealth Advisors first reported a position in Arcutis Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • TCI Wealth Advisors's Arcutis Biotherapeutics position peaked at $4.07K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.